REFERENCES
- Andrić V., Lakić D., Petrova G. (2009) Arh. Farm., 59, 13–26.
- Black H.R., Elliott W.J., Grandits G., et al.. (2003) JAMA, 289(16), 2073–2082.
- Briggs A., Claxton K., Sculpher M. (2006) Decision modeling for economic evaluation, Oxford University Press, New York, pp. 51–120.
- Brown M.J., Palmer C.R., Castaigne A., et al.. (2000) Lancet, 356(9227), 366–372.
- Campbell H.M., Boardman K.D., Dodd M.A., Raisch D.W. (2007) Ann. Pharmacother., 41, 1101–1110.
- Carroll C.A., Coen M.M., Piepho R.W. (2003) Ann. Pharmacother., 37, 327–331.
- CEA Registry, https://research.tufts-nemc.org/cear/Default.aspx (Accessed: 16.02.2011)
- Cheung C.M., Tsoi T.H., Hon S.F.K., et al.. (2007) Hong Kong Med. J., 13(2), 95–99.
- Chobanian A.V., Bakris G.L., Black H.R., et al.. (2003) JAMA., 289, 2560–2572.
- Cohn J., Johnson G., Ziesche S., et al.. (1991) n. Engl. J. Med., 395(5), 303–310.
- D'Agostino R.B., Russell M.W., Huse D.M., et al.. (2000) Am. heart J., 139(2), 272–281.
- Dahlof B., Devereux R.B., Kjeldsen S.E., et al.. (2002) lancet, 359(9311), 995–1003.
- Dahlof B., Sever P.S., Poulter N.R., et al.. (2005) Lancet, 366(9489), 895–906.
- Drummond M.F., Sculpher M.J., Torrance G.W., et al.. (2005) Methods for the economic evaluation of health care Programmes, 3rd ed, Oxford University Press, New York, p. 9.
- Flack J.M., Casciano R., Casciano J., et al.. (2002) Manag. care. Interface., 15, 28–36.
- Gandjour A., Stock S. (2007) health Policy, 83, 257–267.
- Gueyffier F., Boissel J.P., Boutitie F., et al.. (1997) Stroke, 28, 2557–2562.
- Gueyffier F., Boutitie F., Boissel J.P., Pocock S., Coope J., Cutler J., et al.. (1997) Ann. intern. Med., 126, 761–777.
- Hansson L., Hedner T., Lund-Johansen P., et al.. (2000) Lancet, 356(9227), 359–365.
- Hansson L., Lindholm L.H., Ekborn T., Dahlöf B., Lanke J., Scherstén B., et al.. (1999) Lancet, 354, 1751–1756.
- Hansson L., Lindholm L.H., Niskannen L., et al.. (1999) Lancet, 353(9153), 611–616.
- Hansson L., Lloyd A., Anderson P., et al.. (2002) Blood. Press., 11, 35–45.
- Hjalmarson A., Goldstein S., Fagerberg B., et al.. (2000) JAMA, 283(10), 1295–302.
- Institute of Public Health of Serbia (2009) Incidence and mortality of acute coronary syndrome in Serbia 2008, Belgrade, Serbia.
- Institute of Public Health of Serbia. Monitoring of the quality of health care—selected indicators in Serbia 2005–2009, http://www.batut.org.rs/index.php?content=61 (Accessed: 28.09.2010) (in Serbian)
- Institute of Statistics of Republic of Serbia. Detailed mortality tables, http://webrzs.stat.gov.rs/axd/stanovnistvo/izbor.htm (Accessed: 28.09.2010) (in Serbian)
- Ivannova A., Lakić D., Andrić V., et al.. (2009) Pharm. Pract., 7, 108–112.
- Julius S., Kjeldsen S.E., Weber M., et al.. (2004) Lancet, 363(9426), 2022–2031.
- Kaerney P.M., Whelton M., Reynolds K., et al.. (2005) Lancet, 365, 217–223.
- Lakic D., Bogavac-Stanojevic N., Jelic-Ivanovic Z., et al.. (2010) Value. health., 13, 770–777.
- Leal J., Luengo-Fernandez R., Gray A., et al.. (2006) Eur. heart. J., 27, 1610–1619.
- Lloyd A., Schmieder C., Marchant N. (2003) Pharmacoeconomics, 21(Suppl. 1), 33–41.
- Lothgren M., Zethraeus N. (2000) health. Econ., 9, 623–630.
- Mancia G., De Backer G., Dominiczak A., et al.. (2007) J. Hypertens., 25, 1105–1187.
- Mar J., Rodriguez-Artalejo F. (2001) J. Hypertens., 19, 149–155.
- Marković B.B., Kranjčević K., Stojanović-Špehar S., et al.. (2009) Coll. Antropol., 33, 71–76.
- Ministry of Health of Republic of Serbia (2006) Health survey of the Republic of Serbia 2006, Final Report, http://www.zdravlje.gov.rs/showpage.php?id=142 (Accessed: 10.07.2010) (in Serbian)
- Ministry of Health of Republic of Serbia (2011) Arterial hypertension—guidelines, http://www.zdravlje.gov.rs/showpage.php?id=145 (Accessed: 12.05.2011) (in Serbian)
- Montgomery A.A., Fahey T., Ben-Shlomo Y., et al.. (2003) J. Hypertens., 21, 1753–1759.
- Murray C.J.L., Lauer J.A., Hutubessy R.C.W., et al.. (2003) Lancet, 361, 717–725.
- National Collaborating Centre for Chronic Conditions (2006) hypertension: Management in Adults in Primary care: Pharmacological Update, Royal college of Physicians, London.
- Neal B., MacMahon S., Chapman N. (2000) Lancet, 356, 1955–1964.
- Nordmann A.J., Krahn M., Logan A.G., et al.. (2003) Pharmacoeconomics, 21, 573–585.
- Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al.. (2003) JAMA, 290(21), 2805–2816.
- Petiti D. (2000) Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis, 2nd Ed., Oxford University Press, New York, p. 145–155.
- Psaty B.M., Lumley T., Furberg C.D., et al.. (2003) JAMA, 289, 2534–2544.
- Shaffer P.A., Haddix A.C. (1996) In: Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation (A.C. haddix, S.M. Teutsch, P.A. Shaffer, D.O. Dunet, Eds.), Oxford University Press, New York, 76–84.
- Staessen J.A., Wang J.G., Thijs L. (2003) J. hypertens., 21, 1055–1076.
- Stafilas P.C., Serafidid P.A., Lasaridis A.N., et al.. (2005) Am. J. Hypertens., 18, 1233–1240.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) JAMA, 288(23), 2981–2997.
- The SOLVD investigators (1991) N. Engl. J. Med., 395(5), 293–302.
- Tran K., Ho C., Noorani H.Z., et al.. (2007) Thiazide diuretics as first-line treatment for hypertension: metaanalysis and economic evaluation [Technology report number 95], Canadian Agency for Drugs and Technologies in Health, Ottawa.
- Weber M.A., Bakris G.L., Jamerson K., et al.. (2010) J. Am. Coll. Cardiol., 56(1), 77–85.
- Williams B., Poulter N.R., Brown M.J., et al.. (2004) J. Hum. Hypertens., 18, 139–185.
- Wright J.M., Musini V.M. (2009) Cochrane Database of Systematic Reviews, 3, Art. No.: CD001841. DOI: 10.1002/14651858.CD001841.pub2.